PFMU
BMY.RT

Privium Fund Management (UK)’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Privium Fund Management (UK)’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-46,933
Closed -$55K – 88
2020
Q4 		$55K Buy
+46,933
New +$100K 0.04% 42

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Privium Fund Management (UK)'s BMY.RT Position: Q1 2021 in Review

Privium Fund Management (UK) sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 46,933 shares — an estimated $55K sold.

Privium Fund Management (UK) first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $55K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Privium Fund Management (UK) reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Privium Fund Management (UK) sold 46,933 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $55K.
  • Privium Fund Management (UK) first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Privium Fund Management (UK)'s Bristol-Myers Squibb Company Contingent Value Rights position peaked at $55K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Privium Fund Management (UK)'s 13F filing for Q1 2021, filed 11 May 2021.